866-997-4948(US-Canada Toll Free)

Global Metabolic Disorders Therapeutics Market 2016-2020

Published By :

Technavio

Published Date : Sep 2016

Category :

Cardiovascular Devices

No. of Pages : 163

About Metabolic Disorders

Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

Technavios analysts forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lilly

Other prominent vendors
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma
Arena Pharmaceuticals
Astellas Pharma
Atheronova
Aurobindo Pharma
Baxalta
Belrose Pharma
BHV Pharma
Biocon
Biodel
BioMarin
Bionaturis
Biosidus
Biospherics
Boehringer Ingelheim
Bristol-Myers Squibb
Catabasis Pharmaceuticals
Cerenis Therapeutics
Chipscreen Biosciences
Cipla
CJ HealthCare
CKD Bio
Concord Biotech
ConjuChem
CureDm
CymaBay Therapeutics
Daewoong
Daiichi Sankyo
Dance Biopharm
DiaMedica
Diamyd Therapeutics
Diasome Pharmaceuticals
DiaVacs
Dong-A ST
Eisai
Elcelyx Therapeutics
Esperion Therapeutics
Exsulin
F. Hoffmann-La Roche
Gan & Lee Pharmaceuticals
Generex Biotechnology
Genfit
GlaxoSmithKline
HanAll BioPharma
Hanmi Pharmaceutical Company
Hua Medicine
Iltoo Pharma
Intarcia Therapeutics
InteKrin Therapeutics
Intrexon
Ionis Pharmaceuticals
Islet Sciences
ISU Abxis
Janssen Pharmaceuticals
Japan Tobacco
JCR Pharmaceuticals
JW Pharmaceuticals
Kadmon Pharmaceuticals
Kamada
KinDex Pharmaceuticals
Kissei
Kotobuki
Kowa Company
Laboratoires SMB
Lexicon Pharmaceuticals
Ligand Pharmaceuticals
Living Cell Technologies
Livzon
LIXTE Biotechnology
Lupin
MacroGenics
Madrigal Pharmaceuticals
MannKind
MedImmune
Melior Pharmaceuticals
Merrion Pharmaceuticals
Merz Pharmaceuticals
Metabolic Solutions Development Company
Mitsubishi Tanabe Pharma
Mylan
Neothetics
Neuraltus Pharmaceuticals
NGM Biopharmaceuticals
NGM Biopharmaceuticals
Norgine BV
Novartis
NuSirt Biopharma
Oramed
Orexigen Therapeutics
Osiris Therapeutics
Peptron
Perle Biosciences
Pfizer
PhaseBio Pharmaceuticals
Poxel
Protalix Biotherapeutics
Raptor
Recordati
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
REGiMMUNE
Rhythm Pharmaceuticals
Saniona
Santaris Pharma
Santaris Pharma
Serometrix
Shionogi
Shire
Sigma-Tau
Sirona Biochem
Strongbridge Biopharma
SUN Pharma
Takeda
Teva
Thera technologies
Theracos
Toleranzia
Tolerion
Torrent Pharmaceuticals
Transition Therapeutics
UCB
Utrecht Holdings
VeroScience
Vivus
vTv Therapeutics
XBiotech
Xeris Pharmaceuticals
XOMA
Zafgen
Zydus Cadila

Market driver
Increase in academia-industry collaborations for drug development
For a full, detailed list, view our report

Market challenge
Low compliance and adherence rates
For a full, detailed list, view our report

Market trend
Increase in academia-industry collaborations for drug development
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Pipeline portfolio
Pipeline portfolio: Global diabetes drugs market
Pipeline portfolio: Global hyperphosphatemia drugs market
Pipeline portfolio: Global anti-obesity drugs market
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Market segmentation by type of disease
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases
PART 08: Global diabetes drugs market
Market overview
Global type 1 diabetes market
Global type 2 diabetes drugs market
Vendors in global diabetes drugs market
PART 09: Global hypercholesterolemia drugs market
Market overview
Vendors in global hypercholesterolemia drugs market
PART 10: Global lysosomal storage diseases market
Market overview
Vendors in global lysosomal storage disorders drugs market
PART 11: Global anti-obesity drugs market
Market overview
Vendors in global anti-obesity drugs market
PART 12: Geographical segmentation
Global metabolic disorders therapeutics market by geography 2015-2020
Metabolic disorders therapeutics market in Americas
Metabolic disorders therapeutics market in EMEA
Metabolic disorders therapeutics market in APAC
PART 13: Market drivers
Patient assistance programs
Special regulatory designations for rare diseases
Increase in academia-industry collaborations for drug development
PART 14: Impact of drivers
PART 15: Market challenges
Low compliance and adherence rates
High cost of therapies
Complex storage conditions and distribution policies for insulin
PART 16: Impact of drivers and challenges
PART 17: Market trends
Focus on oral insulin therapies
Strong and diversified pipeline portfolio
Strategic collaborations and acquisitions
PART 18: Vendor landscape
Competitive scenario
Other prominent vendors
PART 19: Key vendor analysis
Novo Nordisk
Sanof
Merck
AstraZeneca
Eli Lilly
PART 20: Appendix
List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions)
Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market
Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis
Exhibit 08: Five forces analysis
Exhibit 09: Global metabolic disorders therapeutics market by type of disease
Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020)
Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis
Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions)
Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions)
Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 17: Market share analysis of vendors in global diabetes drugs market
Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 20: Market dynamics of hypercholesterolemia drugs
Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015
Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market
Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
Exhibit 26: Key events in treatment of lysosomal storage diseases
Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market
Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions)
Exhibit 29: Products offered by major vendors in global anti-obesity drugs market
Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020
Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020
Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015
Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Prevalence of obesity in various countries in Europe 2025
Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025
Exhibit 41: Few metabolic disorder drugs with patient assistance programs
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Oral insulin pipeline portfolio
Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms
Exhibit 46: Key vendors ranking 2015
Exhibit 47: Geographical presence of key vendors
Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
Exhibit 49: Novo Nordisk: Profile
Exhibit 50: Novo Nordisk: Strength analysis
Exhibit 51: Novo Nordisk: Growth strategy matrix
Exhibit 52: Novo Nordisk: Growth opportunity assessment
Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care
Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
Exhibit 62: Sanofi: Business segmentation by revenue 2015
Exhibit 63: Sanofi: Profile
Exhibit 64: Sanofi: Strength analysis
Exhibit 65: Sanofi growth strategy matrix
Exhibit 66: Sanofi: Growth opportunity assessment
Exhibit 67: Key product offerings in diabetes market ($ billions)
Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
Exhibit 74: Merck: Strength profile
Exhibit 75: Merck: Strength analysis
Exhibit 76: Merck: Growth strategy matrix
Exhibit 77: Merck: Opportunity assessment
Exhibit 78: Top selling diabetes drugs in 2015
Exhibit 79: Merck: Diabetes segmentation by revenue 2015
Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 85: AstraZeneca: Profile
Exhibit 86: AstraZeneca: Strength analysis
Exhibit 87: AstraZeneca: Growth strategy matrix
Exhibit 88: AstraZeneca: Opportunity assessment
Exhibit 89: Top selling diabetes drugs in 2015 ($ billions)
Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
Exhibit 96: Eli Lilly: Profile
Exhibit 97: Eli Lilly: Strength analysis
Exhibit 98: Eli Lilly growth strategy matrix
Exhibit 99: Eli Lilly: Opportunity assessment
Exhibit 100: Top selling diabetic drugs 2015 ($ billions)
Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *